Sung Won Song
Directeur/Bestuurslid bij JW (CAYMAN) THERAPEUTICS CO. LTD
Actieve functies van Sung Won Song
| Bedrijven | Functie | Begin | Einde |
|---|---|---|---|
| JW (CAYMAN) THERAPEUTICS CO. LTD | Directeur/Bestuurslid | 29-08-2023 | - |
EpimAb Biotherapeutics, Inc.
 EpimAb Biotherapeutics, Inc. Pharmaceuticals: MajorHealth Technology EpimAb Biotherapeutics, Inc. is a Chinese clinical stage biopharmaceutical company that specializes in developing multispecific antibodies. The company is based in Shanghai, China. The company utilizes its in-house research and technology capabilities, including the proprietary fit-ig® and mat-fab bispecific platforms, to generate and advance a unique pipeline of transformative preclinical and clinical assets that aim to benefit cancer patients. The company was founded in 2016 by Chen Bing Wu, who has been the CEO since 2016. | Directeur/Bestuurslid | - | - |
Loopbaan van Sung Won Song
Opleiding van Sung Won Song
| Korea University | Undergraduate Degree |
| The Trustees of Columbia University in The City of New York | Graduate Degree |
| The Ohio State University | Doctorate Degree |
Statistieken
Internationaal
| China | 3 |
| Verenigde Staten | 3 |
| Zuid-Korea | 2 |
Operationeel
| Director/Board Member | 2 |
| Undergraduate Degree | 1 |
| Graduate Degree | 1 |
Sectoraal
| Consumer Services | 4 |
| Health Technology | 3 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| JW (CAYMAN) THERAPEUTICS CO. LTD | Health Technology |
| Bedrijven in privébezit | 1 |
|---|---|
EpimAb Biotherapeutics, Inc.
EpimAb Biotherapeutics, Inc. Pharmaceuticals: MajorHealth Technology EpimAb Biotherapeutics, Inc. is a Chinese clinical stage biopharmaceutical company that specializes in developing multispecific antibodies. The company is based in Shanghai, China. The company utilizes its in-house research and technology capabilities, including the proprietary fit-ig® and mat-fab bispecific platforms, to generate and advance a unique pipeline of transformative preclinical and clinical assets that aim to benefit cancer patients. The company was founded in 2016 by Chen Bing Wu, who has been the CEO since 2016. | Health Technology |
- Beurs
- Insiders
- Sung Won Song
- Ervaring
